Pediatric Brain Tumor Market

By Product Type;

Gliomas, Mixed Neuronal-Glial Tumors, Embryonal Tumors, Choroid Plexus Papilloma/Carcinoma, Tumors Arising From Non-Neuroepithelial Tissue, Meningeal Tumors, and Others

By Diagnosis;

Physical Exam, Imaging Tests, Brain or Spinal Cord Tumor Biopsy, Lumbar Puncture (Spinal Tap), Blood and Urine Tests, and Others

By Treatment;

Surgery, Therapies, and Others

By End User;

Hospitals and Clinics, Medical Research Centers, Academic Institutes, and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn898679670 Published Date: August, 2025 Updated Date: September, 2025

Pediatric Brain Tumor Market Overview

Pediatric Brain Tumor Market (USD Million)

Pediatric Brain Tumor Market was valued at USD 1,505.66 million in the year 2024. The size of this market is expected to increase to USD 1,941.68 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 3.7%.


Pediatric Brain Tumor Market

*Market size in USD million

CAGR 3.7 %


Study Period2025 - 2031
Base Year2024
CAGR (%)3.7 %
Market Size (2024)USD 1,505.66 Million
Market Size (2031)USD 1,941.68 Million
Market ConcentrationHigh
Report Pages369
1,505.66
2024
1,941.68
2031

Major Players

  • Abbott
  • AbbVie Inc
  • Akorn
  • Agios

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Pediatric Brain Tumor Market

Fragmented - Highly competitive market without dominant players


The Pediatric Brain Tumor Market is strengthening as providers emphasize timely diagnosis, tailored treatments, and family-centric support. Over 62% of organizations now rely on coordinated care pathways to elevate clinical outcomes and life quality, reflecting a clear pivot to specialized pediatric oncology solutions.

Next-Wave Tools Improving Precision
Innovation in genomic testing, machine-learning image analysis, and targeted drug design is redefining standards. Nearly 56% of facilities deploy molecular stratification and adaptive planning to boost accuracy. Enhanced intraoperative guidance and neuro-monitoring further support safer intervention.

Connected Ecosystems and Data-Led Decisions
About 54% of stakeholders integrate tele-oncology, ePRO tracking, and shared registries to align teams and accelerate evidence generation. Real-world datasets paired with AI-enabled triage are expediting trial enrollment and improving care coordination.

Outlook: Targeted Growth Vectors
More than 50% of innovators are advancing biomarker-informed regimens, immune-based combinations, and high-resolution imaging. Momentum in precision dosing, digital follow-up, and survivorship analytics signals strong opportunities for offerings that couple effectiveness with long-term safety.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Product Type
    2. Market Snapshot, By Diagnosis
    3. Market Snapshot, By Treatment
    4. Market Snapshot, By End User
    5. Market Snapshot, By Region
  4. Pediatric Brain Tumor Market Trends Dinamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Precision Medicine
        2. Molecular Profiling
        3. Targeted Therapy
        4. Immunotherapy
      2. Restraints
        1. Limited Funding
        2. Treatment Toxicities
        3. Tumor Heterogeneity
        4. Access to Innovative Therapies
      3. Opportunities
        1. Precision Oncology
        2. Biomarker Discovery
        3. Immunotherapy Advancements
        4. Targeted Therapies Development
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry

  5. Market Segmentation
    1. Pediatric Brain Tumor Market, By Product Type, 2021 - 2031(USD Million)
      1. Gliomas
      2. Mixed Neuronal-Glial Tumors
      3. Embryonal Tumors
      4. Choroid Plexus Papilloma/Carcinoma
      5. Tumors Arising From Non-Neuroepithelial Tissue
      6. Meningeal Tumors
      7. Others
    2. Pediatric Brain Tumor Market, By Diagnosis, 2021 - 2031 (USD Million)
      1. Physical Exam
      2. Imaging Tests
      3. Brain Or Spinal Cord Tumor Biopsy
      4. Lumbar Puncture (Spinal Tap)
      5. Blood And Urine Tests
      6. Others
    3. Pediatric Brain Tumor Market, By Treatment, 2021 - 2031 (USD Million)
      1. Surgery
      2. Therapies
      3. Others
    4. Pediatric Brain Tumor Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals and Clinics
      2. Medical Research Centers
      3. Academic Institutes
      4. Others
    5. Pediatric Brain Tumor Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Abbott
      2. AbbVie Inc
      3. Akorn Inc
      4. Agios Inc
  7. Analyst Views
  8. Future Outlook of the Market